BAROnova, Inc., is a clinical-stage medical-device company focused on developing non-surgical non-pharmacologic devices to induce weight loss.
BAROnova® recently closed a Series D financing of $36.5 million to continue the clinical development of the TransPyloric Shuttle® weight-loss system.* This technology focuses on potentially slowing a person’s gastric emptying, which is a known mechanism of action for weight loss. In December 2015, BAROnova began enrolling patients in the ENDObesity® II Study, a twelve-month multicenter pivotal clinical trial designed to test the safety and effectiveness of the TransPyloric Shuttle.
'+p(a[c].innerHTML)+"
",y&&(b=J?b+(''+f[c].getAttribute("aria-label")+"
"):b+(''+f[c].getAttribute("aria-label")+"
"))):a[c].innerText?(t&&(b+=''+k[c].innerText+"
"),b+=''+a[c].innerText+"
",y&&(b+=''+f[c].innerText+"
")): (t&&(b+=''+k[c].textContent+"
"),b+=''+a[c].textContent+"
",y&&(b+=''+f[c].textContent+"
"));H&&(b+='':">")+'Reply':">")+'Retweet':">")+"Favorite
");I&&void 0!==h[c]&&(b+='© 2016 All Rights Reserved By Biotech and Money